Issue | Pharma's Almanac

Current Issue: Q1 2017

Market Landscape

Also In This Issue

Innovation and Partnership Through Experience and Acquisition

The pharmaceutical marketplace is more global than ever and, as companies fight for market share in this increasingly competitive landscape, contract development and manufacturing organizations (CDMOs) are becoming more important than ever. However, competition amongst CDMOs is also mounting. Those looking to stand out in this crowded space must remain nimble, customer-focused and, above all […]

Coping with the Data Avalanche

Q1 2017: A Note from the Editor One of the most memorable compliments I received in my 14 years as editor of Speciality Chemicals Magazine came from an American executive at a trade show. He told me he had boarded a plane with a pile of about 15 chemical industry magazines and when he got […]

The Data Generation

The pharmaceutical market landscape remains tremendously dynamic in 2017. Outsourcing practices for drug discovery, product and process development, clinical trials and manufacturing continue to evolve as well. Data — ‘Big Data’ in particular — is facilitating much of the changes, from the effectiveness of outsourcing to paradigm shifts in manufacturing. The first issue of Pharma’s […]

Big Data: A Big Challenge

There is almost no aspect of the life sciences and related industries that Big Data cannot impact. It can help in disease pattern analysis by bringing information together in new ways; it facilitates drug discovery by enabling advanced search capabilities for analyzing millions of publications, patents and clinical trial documents; it can also help in […]

Energizing Client Portfolios with Patient-Friendly Dosage Forms

Patient noncompliance is extremely costly in terms of reduced patient health and lost revenue opportunity. SPI Pharma offers excipient technologies and drug development services supporting the formulation of patient-friendly oral dosage forms designed to address this crucial issue. Patient noncompliance costs the pharmaceutical industry approximately $564 billion annually.1 Despite the fact that patients typically prefer […]

Continuous Manufacturing: To Be Continued…

Continuous manufacturing offers obvious advantages to the pharmaceutical sector but has not yet evolved into a major alternative to batch. Are things about to change? Dr. Andrew Warmington spoke with some of the leading CDMOs and API manufacturers to find out how the landscape is shifting. “I don’t know why it’s not more widely used… […]

Past Issues

View all Past Issues

The Innovation Issue

View Issue »

Issue #4 | Volume #4 | Q4 2018

Innovative & Expert Partners

View Issue »

Issue #2 | Volume #2 | Q2 2016

The Outsourcing Issue

View Issue »

Issue #3 | Volume #6 | Q3 2020

Future Pharma Partner Models

View Issue »

Issue #3 | Volume #3 | Q3 2017